Cochrane · systematic review · CD006649

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer

Kahale, LA, Matar, CF, Hakoum, MB, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

Gynaecological, Neuro-oncology and Orphan Cancer7 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 14 · 58.3%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 37.5%Moderate 1 · 4.2%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 7 versions

Low molecular weight heparin compared to unfractionated heparin

Population: people with cancer with venous thromboembolism (VTE)

8 questions

Outcome	Effect	Evidence	Status / GRADE
Outcomes Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies
Mortality Low molecular weight heparin vs unfractionated heparin	RR 0.66 [0.4, 1.1]	5 studies · 418 participants	Low Downgraded: imprecision
Recurrent VTE Low molecular weight heparin vs unfractionated heparin	RR 0.69 [0.27, 1.76]	3 studies · 422 participants	Low Downgraded: imprecision
Major bleeding ‐ not reported Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies
Minor bleeding ‐ not reported Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies
Quality of life ‐ not reported Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies
Postphlebitic syndrome ‐ not reported Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies
Thrombocytopenia ‐ not reported Low molecular weight heparin vs unfractionated heparin	no estimate extracted	NR	No studies

Fondaparinux compared to heparin

Population: people with cancer with VTE

8 questions

Outcome	Effect	Evidence	Status / GRADE
Outcomes Fondaparinux vs heparin	no estimate extracted	NR	No studies
Mortality Fondaparinux vs heparin	RR 1.25 [0.86, 1.81]	1 study · 477 participants	Low Downgraded: imprecision
Recurrent VTE Fondaparinux vs heparin	RR 0.93 [0.56, 1.54]	1 study · 477 participants	Low Downgraded: imprecision
Major bleeding Fondaparinux vs heparin	RR 0.82 [0.4, 1.66]	1 study · 477 participants	Low Downgraded: imprecision
Minor bleeding Fondaparinux vs heparin	RR 1.53 [0.88, 2.66]	1 study · 477 participants	Moderate Downgraded: imprecision
Quality of life ‐ not reported Fondaparinux vs heparin	no estimate extracted	NR	No studies
Postphlebitic syndrome ‐ not reported Fondaparinux vs heparin	no estimate extracted	NR	No studies
Thrombocytopenia ‐ not reported Fondaparinux vs heparin	no estimate extracted	NR	No studies

Dalteparin compared to tinzaparin

Population: initial treatment in people with cancer with VTE

8 questions

Outcome	Effect	Evidence	Status / GRADE
Outcomes Dalteparin vs tinzaparin	no estimate extracted	NR	No studies
Mortality Dalteparin vs tinzaparin	RR 0.86 [0.43, 1.73]	1 study · 113 participants	Low Downgraded: imprecision
Recurrent VTE Dalteparin vs tinzaparin	RR 0.44 [0.09, 2.16]	1 study · 113 participants	Low Downgraded: imprecision
Major bleeding Dalteparin vs tinzaparin	RR 2.19 [0.2, 23.42]	1 study · 113 participants	Low Downgraded: imprecision
Minor bleeding Dalteparin vs tinzaparin	RR 0.82 [0.3, 2.21]	1 study · 113 participants	Low Downgraded: imprecision
Quality of life ‐ not reported Dalteparin vs tinzaparin	no estimate extracted	NR	No studies
Postphlebitic syndrome ‐ not reported Dalteparin vs tinzaparin	no estimate extracted	NR	No studies
Thrombocytopenia ‐ not reported Dalteparin vs tinzaparin	no estimate extracted	NR	No studies